Loading clinical trials...

Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection

NCT01126268•The University of Texas Health Science Center, Houston

View on ClinicalTrials.gov

Summary

The purpose of this study is to document the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with bacterial infections, including impetigo, folliculitis, and minor soft tissue infections including secondarily infected eczema presumed to be caused by methicillin resistant Staph aureus. Male and female patients ages 9 months to 98 years will be recruited from a university based dermatology clinic. Upon enrollment, wound cultures will be collected, and then subjects will apply topical retapamulin twice daily for five days. The primary endpoint will be resolution of methicillin-resistant Staphylococcus aureus (MRSA) infection based on clinical presentation and physical exam, as well as bacteriological efficacy based on culture results. It is anticipated that approximately 75 patients will be enrolled, with expectation that approximately 50 of these patients will have MRSA infections.

Eligibility

Age

0 - 98 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female patients from 9 months of age up to 98 years of age.
•Clinical diagnosis of impetigo, folliculitis, or minor soft tissue infection including secondarily infected eczema presumed to be caused by Staphylococcus aureus.
•The patient, and if applicable the parent or guardian, is able to give informed consent
•Females of child bearing potential have a negative urine pregnancy test.
•Patient, and if applicable parent or guardian, are willing to and capable of complying with the study protocol.

Exclusion Criteria

•Subject who has used a topical antibacterial medication to the area being treated within the last 48 hours.
•Subject who has been enrolled in a clinical trial within the last 30 days.
•Subject with signs of systemic infection (such as fever), or with evidence of abscess or cellulitis at the site to be treated.
•Subject has a bacterial skin infection which would not be appropriately treated by a topical antibiotic in the opinion of the investigator
•Subjects who have taken oral antibiotics within the last 7 days.
•Subjects with known sensitivity to the study medication.
•The subject is pregnant or breastfeeding

Locations (1)

Houston Medical Center Building

Houston, Texas, United States

Key Dates

Start Date

April 1, 2010

Primary Completion Date

November 1, 2012

Completion Date

November 1, 2012

Last Updated

February 17, 2016

Enrollment

ACTUAL participants

Conditions

ImpetigoFolliculitisSecondarily Infected EczemaMinor Soft Tissue Infections

Interventions

Retapamulin (Altabax)

DRUG

Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

NCT02090764

Impetigo

View study

COMPLETEDNA

Evaluation of Safety and Performance of Ialuxid Gel in Treatment of Acne Vulgaris, and Folliculitis

NCT05345093

Acne VulgarisFolliculitis

View study

COMPLETEDPHASE4

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 17, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection

Inclusion Criteria

Exclusion Criteria

Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

Evaluation of Safety and Performance of Ialuxid Gel in Treatment of Acne Vulgaris, and Folliculitis

Efficacy and Safety of 30% Supramolecular Salicylic Acid Combined With Supramolecular Active Zinc in the Treatment of Malassezia Folliculitis

Investigation of the Effect of Vitamin K3-lotion for the Treatment of Cetuximab Induced Folliculitis

Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment

Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo